RP-323
Acute Respiratory Distress Syndrome (ARDS)
Key Facts
About PhorMed
PhorMed is a private, pre-revenue biotech developing RP-323, a novel cell repair therapy targeting inflammation across oncology, neurology, and pulmonology. The company is preparing for multiple Phase 2 trials in ARDS, Parkinson's, AML, and HL, supported by recent partnerships and an equity crowdfunding campaign. Led by CEO Ben Chang and scientific founder Professor Richard L. Chang, PhorMed's strategy hinges on securing funding to advance its clinical programs and validate its platform.
View full company profileAbout PhorMed
PhorMed is a private, pre-revenue biotech developing RP-323, a novel cell repair therapy targeting inflammation across oncology, neurology, and pulmonology. The company is preparing for multiple Phase 2 trials in ARDS, Parkinson's, AML, and HL, supported by recent partnerships and an equity crowdfunding campaign. Led by CEO Ben Chang and scientific founder Professor Richard L. Chang, PhorMed's strategy hinges on securing funding to advance its clinical programs and validate its platform.
View full company profileAbout PhorMed
PhorMed is a private, pre-revenue biotech developing RP-323, a novel cell repair therapy targeting inflammation across oncology, neurology, and pulmonology. The company is preparing for multiple Phase 2 trials in ARDS, Parkinson's, AML, and HL, supported by recent partnerships and an equity crowdfunding campaign. Led by CEO Ben Chang and scientific founder Professor Richard L. Chang, PhorMed's strategy hinges on securing funding to advance its clinical programs and validate its platform.
View full company profileAbout PhorMed
PhorMed is a private, pre-revenue biotech developing RP-323, a novel cell repair therapy targeting inflammation across oncology, neurology, and pulmonology. The company is preparing for multiple Phase 2 trials in ARDS, Parkinson's, AML, and HL, supported by recent partnerships and an equity crowdfunding campaign. Led by CEO Ben Chang and scientific founder Professor Richard L. Chang, PhorMed's strategy hinges on securing funding to advance its clinical programs and validate its platform.
View full company profileTherapeutic Areas
Other Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| BXT-25 | BioXyTran | Preclinical |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |
| Research Grant: Effects of sevoflurane on lung water in ARDS | Sedana Medical | Investigator-Initiated Trial |